Stay updated on Elacestrant in ER+ Advanced Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Elacestrant in ER+ Advanced Breast Cancer Clinical Trial page.

Latest updates to the Elacestrant in ER+ Advanced Breast Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe Denmark location listing was updated to reflect “Region Sjælland,” including the Næstved address line, replacing the previous “Zeeland” wording. This is a administrative/labeling correction to the study sites rather than a change to the trial itself.SummaryDifference0.2%

- Check15 days agoNo Change Detected
- Check37 days agoChange DetectedRevision: v3.5.0 has been added and Revision: v3.4.3 has been removed.SummaryDifference0.0%

- Check52 days agoChange DetectedAdded a publication citation for the EMERALD trial (JCO 2022). Removed an Erratum entry related to that publication.SummaryDifference0.0%

- Check73 days agoChange DetectedFooter revision updated from v3.4.1 to v3.4.2. No substantive changes to the study details or page layout are observed.SummaryDifference0.0%

- Check80 days agoChange DetectedPublication reference updated: EMERALD JCO 2022 article added with Erratum and older version removed. Page revision updated from v3.4.0 to v3.4.1.SummaryDifference0.0%

- Check94 days agoChange DetectedThe page now shows a glossary toggle and new metadata fields such as 'Last Update Submitted that Met QC Criteria' and 'Last Update Posted', plus a 'No FEAR Act Data' item and a 'Revision: v3.4.0' note.SummaryDifference0.1%

Stay in the know with updates to Elacestrant in ER+ Advanced Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Elacestrant in ER+ Advanced Breast Cancer Clinical Trial page.